GLP-1 Tirzepatide Therapy

What it is

A physician-supervised medical treatment using Tirzepatide, a dual GIP + GLP-1 receptor agonist that supports metabolic health, weight reduction, and appetite regulation. Tirzepatide mimics naturally occurring gut hormones that signal satiety and improve insulin sensitivity, leading to sustainable fat loss and improved glucose control.

How it works

• Dual action: Combines GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) pathways to enhance insulin response, slow gastric emptying, and reduce appetite.
• Metabolic reset: Improves blood sugar control, decreases cravings, and helps the body shift from fat storage to fat burning.
• Gradual titration: Dosing begins low and increases under medical supervision to minimise side effects while optimising results.

What it treats & benefits

• Weight management: Helps reduce body fat and overall weight when combined with a healthy lifestyle.
• Improved glucose regulation: Originally developed for Type 2 diabetes, Tirzepatide improves insulin sensitivity even in non-diabetic patients.
• Cardiometabolic support: Lowers cholesterol and triglycerides, improving cardiovascular markers.
• Sustained appetite control: Patients often report feeling full faster and staying satisfied longer.

What to expect

• Administration: Once-weekly subcutaneous injection performed in-office or at home (depending on prescription plan).
• Onboarding: Requires prior GLP-1 consultation and baseline bloodwork.
• Timeline: Visible changes often begin within 4–8 weeks; optimal results achieved over 3–6 months with consistent use and lifestyle support.
• Monitoring: Regular follow-ups for dose adjustment, side-effect review, and progress tracking.

Potential side effects

Mild nausea, reduced appetite, constipation, or fatigue may occur initially and typically subside as the body adapts. Serious reactions are rare but will be discussed during consultation (e.g., history of medullary thyroid carcinoma or pancreatitis).

Ideal candidate

• Adults seeking physician-guided medical weight loss or metabolic optimisation
• Patients with BMI ≥ 27 (with comorbidities) or ≥ 30 without
• Individuals ready to combine medication with lifestyle modifications for lasting change